Marker Therapeutics is trading at $1.16, up 11.06%, after announcing a $2.6 million FDA grant. - On October 19, the company announced the non-dilutive funding to support a Phase 1 study of MT-601 for locally advanced, unresectable pancreatic cancer. - The company expects the study to begin in Q1 2027. - Biotech strength is also present in the market context, but the grant is the more direct explanation for the move.